BioCentury
ARTICLE | Financial News

ProQR Therapeutics raises $20M

December 1, 2017 9:49 PM UTC

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $20 million on Nov. 14 through the sale of 5 million shares in a public offering and 1.4 million shares in a concurrent registered direct offering, each at a price of $3.25 per share. The public offering was underwritten by HC Wainwright & Co and National Securities Corporation. The price is a 6% discount from ProQR's close of $3.47 on Nov. 13, before it priced the offering.

In November, ProQR presented positive top-line results from a Phase Ib trial testing QR-010, the company's lede pulmonary candidate, in cystic fibrosis (CF) at the North American CF Conference (NACFC). The RNA-based oligonucleotide targeting the CF transmembrane conductance regulator (CFTR) has been granted Fast Track and Orphan Drug designation by FDA and Orphan Drug designation by EMA. The company plans to start a Phase II trial in 2018...